SILVER2023

A Foundation Building Strength

aka AFBS   |   Palo Alto, CA   |  www.buildingstrength.org
GuideStar Charity Check

A Foundation Building Strength

EIN: 26-1761329


Mission

A FOUNDATION BUILDING STRENGTH FOR NEMALINE MYOPATHY HAS A MISSION TO FIND TREATMENTS FOR NEMALINE MYOPATHY AND SUPPORT FAMILIES CARING FOR THOSE WITH THIS DEBILITATING MUSCLE MYOPATHY.

Ruling year info

2008

Executive Director

Mr. Marc Guillet

Treasurer

Mrs. Kelly Lloyd

Main address

3825 El Camino Real

Palo Alto, CA 94306 USA

Show more contact info

EIN

26-1761329

Subject area info

Diseases and conditions

Musculoskeletal diseases

Genetic conditions and birth defects

Population served info

Children and youth

Adults

People with disabilities

NTEE code info

Specifically Named Diseases Research (H80)

Alliance/Advocacy Organizations (G01)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms

Communication

Blog

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

NEMALINE MYOPATHY RESEARCH GRANTS

GRANTS AWARDED TO RESEARCH INVESTIGATORS TO FIND A CURE/TREATMENT FOR NEMALINE MYOPATHY.

Population(s) Served
Adults
Children and youth
People with disabilities

ENGAGEMENT CONFERENCE FOR FAMILIES WITH NEMALINE MYOPATHY, CLINICIANS AND RESEARCH INVESTIGATORS

Population(s) Served
Adults
Children and youth
People with disabilities

Where we work

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

A Foundation Building Strength has a laser focused mission to find treatments for Nemaline Myopathy and to support families who have been affected by the debilitating disease.

A Foundation Building Strength has three main strategies for getting to treatment:\r\n\r\n1. Review and analyze previous research accomplishments and develop key strategies for speed to treatment.\r\n2. Raise enough funds to be able to fund research proposals on a bi-annual basis.\r\n3. Provide education and engagement opportunities such as webinars and conferences for families of those affected by Nemaline Myopathy, clinicians and research investigators.

A Foundation has a committed Board of Directors and a strong support community. Although the Nemaline Myopathy community is very small, they are very dedicated to helping find treatments for NM.

We have not yet found a treatment/cure for Nemaline Myopathy. \r\nWe have published the Care Protocol for Congenital Myopathies.\r\nWe host family conferences every year.\r\nWe host a Nemaline Myopathy Conference every other year.\r\nWe have established partnerships with other organizations to help further our quest for NM treatment.\r\nWe participate in the Congenital Myopathy Registry.\r\nWe have funded a Congenital Myopathy Tissue Registry.

Financials

A Foundation Building Strength
Fiscal year: Jan 01 - Dec 31

Revenue vs. expenses:  breakdown

SOURCE: IRS Form 990 info
NET GAIN/LOSS:    in 
Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2022 info

SOURCE: IRS Form 990

20.18

Average of 115.94 over 10 years

Months of cash in 2022 info

SOURCE: IRS Form 990

41.8

Average of 50 over 10 years

Fringe rate in 2022 info

SOURCE: IRS Form 990

0%

Average of 2% over 10 years

Funding sources info

Source: IRS Form 990

Assets & liabilities info

Source: IRS Form 990

Financial data

SOURCE: IRS Form 990

A Foundation Building Strength

Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

Fiscal year ending: cloud_download Download Data

A Foundation Building Strength

Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: cloud_download Download Data

A Foundation Building Strength

Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

This snapshot of A Foundation Building Strength’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Business model indicators

Profitability info 2018 2019 2020 2021 2022
Unrestricted surplus (deficit) before depreciation -$170,867 $140,773 $116,120 $542,973 $1,073,924
As % of expenses -25.2% 46.9% 47.1% 93.0% 140.3%
Unrestricted surplus (deficit) after depreciation -$170,867 $140,773 $116,120 $542,973 $1,073,924
As % of expenses -25.2% 46.9% 47.1% 93.0% 140.3%
Revenue composition info
Total revenue (unrestricted & restricted) $506,009 $440,714 $362,525 $1,126,904 $1,839,492
Total revenue, % change over prior year 10.4% -12.9% -17.7% 210.8% 63.2%
Program services revenue 0.0% 0.0% 0.0% 0.0% 0.0%
Membership dues 0.0% 0.0% 0.0% 0.0% 0.0%
Investment income 1.1% 1.3% 0.1% 0.1% 0.3%
Government grants 0.0% 0.0% 0.0% 0.0% 0.0%
All other grants and contributions 98.6% 99.0% 99.7% 99.9% 99.7%
Other revenue 0.3% -0.3% 0.1% 0.0% 0.0%
Expense composition info
Total expenses before depreciation $676,876 $299,941 $246,405 $583,931 $765,568
Total expenses, % change over prior year 143.7% -55.7% -17.8% 137.0% 31.1%
Personnel 0.0% 0.0% 0.0% 0.0% 0.0%
Professional fees 7.3% 23.4% 21.8% 16.1% 28.1%
Occupancy 0.0% 0.0% 0.0% 0.0% 0.0%
Interest 0.0% 0.0% 0.0% 0.0% 0.0%
Pass-through 90.6% 54.8% 74.1% 80.9% 55.0%
All other expenses 2.2% 21.8% 4.1% 3.0% 16.9%
Full cost components (estimated) info 2018 2019 2020 2021 2022
Total expenses (after depreciation) $676,876 $299,941 $246,405 $583,931 $765,568
One month of savings $56,406 $24,995 $20,534 $48,661 $63,797
Debt principal payment $0 $0 $0 $0 $0
Fixed asset additions $0 $0 $0 $0 $0
Total full costs (estimated) $733,282 $324,936 $266,939 $632,592 $829,365

Capital structure indicators

Liquidity info 2018 2019 2020 2021 2022
Months of cash 20.5 45.2 50.0 30.1 41.8
Months of cash and investments 20.5 45.2 50.0 30.1 41.8
Months of estimated liquid unrestricted net assets 16.3 42.4 57.2 35.3 43.8
Balance sheet composition info 2018 2019 2020 2021 2022
Cash $1,154,532 $1,129,304 $1,026,074 $1,464,989 $2,663,853
Investments $0 $0 $0 $0 $0
Receivables $38,965 $43,221 $65,920 $34,445 $30,322
Gross land, buildings, equipment (LBE) $0 $0 $0 $0 $0
Accumulated depreciation (as a % of LBE) 0.0% 0.0% 0.0% 0.0% 0.0%
Liabilities (as a % of assets) 23.2% 9.9% 3.7% 5.6% 4.6%
Unrestricted net assets $917,807 $1,058,580 $1,174,700 $1,717,672 $2,791,596
Temporarily restricted net assets $0 N/A N/A N/A N/A
Permanently restricted net assets $0 N/A N/A N/A N/A
Total restricted net assets $0 $0 $0 $0 $0
Total net assets $917,807 $1,058,580 $1,174,700 $1,717,672 $2,791,596

Key data checks

Key data checks info 2018 2019 2020 2021 2022
Material data errors No No No No No

Operations

The people, governance practices, and partners that make the organization tick.

Documents
Form 1023/1024 is not available for this organization

Executive Director

Mr. Marc Guillet

Dana and Marc Guillet, who live in Palo Alto, CA gave birth to their third child, Ava, after an uneventful full term pregnancy. With all normal pre-natal visits and amnio testing, their expectations were set for another easy delivery and a short trip home to share Ava with her siblings, Samantha and Andrew.\r\n\r\nAt birth, Ava had some obvious problems. Her hands and feet were mal-positioned and her cry was very weak. The doctors thought because she delivered quickly she would come around within several hours. Three weeks later in the neonatal intensive care unit, Marc and Dana were still learning how to care for their child that had no diagnosis.\r\n\r\nAva could not take milk on her own and on occasion would stop breathing in her sleep. Ava left the hospital with a tube passing from her nose to her stomach for feeding, monitors to tell the Guillets when she stopped breathing, and a suction machine to manage her saliva which she could not swallow. At 7 months, Ava had a feeding tube placed directly through her stomach wall and a muscle biopsy confirming a diagnosis of Nemaline Myopathy.\r\n\r\nAva is currently walking, though she falls more than typical children. She still requires on-going occupational, physical and swallowing therapy on a regular basis. She is 9 and is going into the fourth grade. \r\n\r\nAva is beautiful, happy, bright and certainly tolerant after all of the different doctors and procedures that she has endured.

Treasurer

Kelly Lloyd

Willie Quinn is a life sciences entrepreneur with a passion for making a difference. Willie is CEO and co-founder of Bullet Biotechnology, a company developing a therapeutic vaccine for B-cell lymphomas based on technology invented at Stanford University. Prior to Bullet Biotech, Willie ran Corporate Development for Jazz Pharmaceuticals, a public specialty pharmaceutical company with experience developing and commercializing drugs for orphan indications (indications with fewer than 200,000 patients in the U.S.). Willie joined Jazz Pharmaceuticals in 2003 and actively participated in the creation of their first business plan, working in various functions such as business development, strategy, and finance over his 8 years at the company. Prior to Jazz Pharmaceuticals, Willie was COO and CFO at Novation Biosciences, a venture-backed startup developing software to extract meaningful information from microarray data.\r\n\r\nWillie has an MBA from the Stanford Graduate School of Business and an MA and a BA from Stanford University.

Number of employees

Source: IRS Form 990

A Foundation Building Strength

Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Compensation
Other
Related
Show data for fiscal year
Compensation data
Download up to 5 most recent years of officer and director compensation data for this organization

There are no highest paid employees recorded for this organization.

A Foundation Building Strength

Board of directors
as of 02/02/2023
SOURCE: Self-reported by organization
Board of directors data
Download the most recent year of board of directors data for this organization
Board chair

Marc Guillet

Agile Physical Therapy

Term: 2008 - 2016

Boris Shimanovsky

Factual

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? No
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? No
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? No
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? No
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? No